摘要
背景:热休克蛋白(HSP)是一类在蛋白质折叠过程中起着重要作用的蛋白质。众所周知,HSP还调节了许多关键的凋亡因子。HIG这些蛋白在乳腺癌、前列腺癌、结直肠癌、肺癌、卵巢癌、胃癌、口腔癌和食道癌等多种癌症中均有表达。进行了大量的调查对多种癌症的研究表明,热休克蛋白是癌症中一个很有前途的标志。它们在几种肿瘤中的表达特征表明它们有助于肿瘤的增殖、侵袭、转移和死亡。f癌细胞。检测患者血清中热休克蛋白及其特异性抗体水平对肿瘤的诊断具有重要意义。 目的:介绍和总结热休克蛋白的最新研究进展。它还将突出HSP 27、HSP 60、HSP 70、HSP 90 a的临床和预后特征。ND HSP 110,并将讨论HSP在癌症诊断和预后中的未来意义。此外,还将讨论热休克蛋白作为癌症治疗靶点的作用。在.如果是的话,这篇评论文章将报道各种研究,在这些研究中,热休克蛋白的治疗潜力已经成为研究的目标。 结论:多项实验研究成功地提示了热休克蛋白作为肿瘤临床标志物和治疗靶点的作用。热休克蛋白具有多种癌症特征,如细胞增殖、侵袭和转移等。抑制热休克蛋白已导致成功的治疗结果的癌症。它是一种新颖的反c语言。治疗多种癌症形式的Ancer疗法。然而,需要更多的实验研究来阐明热休克蛋白与其他conv结合的可靠性和有效性。癌症诊断和预后的标记物。通过抑制HSP来进行新的有效干预有望在不久的将来减轻癌症的负担。
关键词: 热休克蛋白,预后,癌症,治疗,细胞增殖,凋亡。
图形摘要
Current Drug Targets
Title:Clinical, Prognostic and Therapeutic Significance of Heat Shock Proteins in Cancer
Volume: 19 Issue: 13
关键词: 热休克蛋白,预后,癌症,治疗,细胞增殖,凋亡。
摘要: Background: Heat Shock Proteins (HSPs) constitute a group of proteins that play a crucial role in the process of protein folding. HSPs are also known to modulate a number of key apoptotic factors. High expression of these proteins is reported in an array of cancers, such as breast, prostate, colorectal, lung, ovarian, gastric, oral and esophageal cancer. Ample amount of investigations were carried out on a variety of cancers suggesting HSPs as a promising hallmark in cancers. Their expression profile in several tumors elucidates that they help in proliferation, invasion, metastasis and death of cancerous cells. Detection of the levels of heat shock proteins and their specific antibodies in the sera of diseased individuals can play an important role in cancer diagnosis.
Objectives: This review will present and summarize latest research being carried out on heat shock proteins. It will also highlight the clinical and prognostic features of HSP27, HSP60, HSP70, HSP90 and HSP110, and will discuss future implications of HSPs in the diagnosis and prognosis of cancer. Furthermore, the role of heat shock proteins as a therapeutic target in cancer will be discussed. In addition, the review article will report various studies, where HSPs have been targeted for their therapeutic potential.
Conclusion: In summary, multiple experimental investigations have been successful in suggesting the role of heat shock protein as a clinical biomarker and therapeutic target in cancer. HSPs are associated with a number of cancer hallmarks such as cell proliferation, invasion and metastasis. Inhibition of HSPs has resulted in successful therapeutic outcome in cancer. It has served as a novel anti-cancer therapy for the treatment of several cancer forms. However, more experimental studies are required to elucidate the reliability and efficacy of heat shock proteins in combination with other conventional markers for cancer diagnosis and prognosis. Novel and effective interventions through HSP inhibition are expected to decrease the burden of cancer in the near future.
Export Options
About this article
Cite this article as:
Clinical, Prognostic and Therapeutic Significance of Heat Shock Proteins in Cancer, Current Drug Targets 2018; 19 (13) . https://dx.doi.org/10.2174/1389450118666170823121248
DOI https://dx.doi.org/10.2174/1389450118666170823121248 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Journals
Related Books
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dietary Manipulation of Precursor Polyunsaturated Fatty Acids Modulates Eicosanoid and Endocannabinoid Synthesis: A Potential Tool to Control Tumor Development
Current Nutrition & Food Science Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Inhibition of Hyaluronan Synthase-3 Decreases Subcutaneous Colon Cancer Growth by Increasing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design The Functions of F-box Proteins in Regulating the Epithelial to Mesenchymal Transition
Current Pharmaceutical Design Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry Vascular Endothelial Growth Factor Receptors [VEGFR] as Target in Breast Cancer Treatment: Current Status in Preclinical and Clinical Studies and Future Directions
Current Topics in Medicinal Chemistry The Mechanisms of Gastric Mucosal Injury: Focus on Microvascular Endothelium as a Key Target
Current Medicinal Chemistry Host Microbiomes in Tumor Precision Medicine: How far are we?
Current Medicinal Chemistry Nanostructural Hybrid Sensitizers for Photodynamic Therapy
Current Pharmaceutical Design Salen Mn Complexes Mitigate Radiation Injury in Normal Tissues
Anti-Cancer Agents in Medicinal Chemistry The Position of Endoscopic Procedures in the Treatment of Obesity
Current Clinical Pharmacology New Therapeutic Platforms for the Treatment of Epithelial and Cutaneous Lesions
Current Drug Delivery Epidemiology of Candida albicans Infections and Role of Non-Candidaalbicans Yeasts
Current Drug Targets Biomarkers of Aging with Prognostic and Predictive Value in Non-Oncological Diseases
Current Medicinal Chemistry Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry HSP60 as a Drug Target
Current Pharmaceutical Design Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Assessment of miR-212 and Other Biomarkers in the Diagnosis and Treatment of HBV-infection-related Liver Diseases
Current Drug Metabolism